This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Sulfametrole is an antibiotic indicated in combination intravenous products for various bacterial infections.
- Generic Name
- Sulfametrole
- DrugBank Accession Number
- DB15975
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Sulfametrole (DB15975)
- Weight
- Average: 286.32
Monoisotopic: 286.019432546 - Chemical Formula
- C9H10N4O3S2
- Synonyms
- Sulfametrole
- External IDs
- 251-288-1
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Bacterial urinary tract infections Combination Product in combination with: Trimethoprim (DB00440) •••••••••••• •••••••• Used in combination to treat Gastrointestinal bacterial infection Combination Product in combination with: Trimethoprim (DB00440) •••••••••••• •••••••• Used in combination to treat Genital infection bacterial Combination Product in combination with: Trimethoprim (DB00440) •••••••••••• •••••••• Used in combination to treat Kidney infection caused by susceptible bacteria Combination Product in combination with: Trimethoprim (DB00440) •••••••••••• •••••••• Used in combination to treat Pneumonia, bacterial Combination Product in combination with: Trimethoprim (DB00440) •••••••••••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcarbose The therapeutic efficacy of Acarbose can be increased when used in combination with Sulfametrole. Acetohexamide The therapeutic efficacy of Acetohexamide can be increased when used in combination with Sulfametrole. Albiglutide The therapeutic efficacy of Albiglutide can be increased when used in combination with Sulfametrole. Alogliptin The therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfametrole. Benzylpenicillin Sulfametrole may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Rokiprim Infusionslösung Sulfametrole (800 mg/250ml) + Trimethoprim (160 mg/250ml) Solution Intravenous Rokitan Gmb H 1979-10-30 Not applicable Austria 
Categories
- ATC Codes
- J01EE03 — Sulfametrole and trimethoprim
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- F5AK41IPQG
- CAS number
- 32909-92-5
- InChI Key
- IZOYMGQQVNAMHS-UHFFFAOYSA-N
- InChI
- InChI=1S/C9H10N4O3S2/c1-16-9-8(11-17-12-9)13-18(14,15)7-4-2-6(10)3-5-7/h2-5H,10H2,1H3,(H,11,13)
- IUPAC Name
- 4-amino-N-(4-methoxy-1,2,5-thiadiazol-3-yl)benzene-1-sulfonamide
- SMILES
- COC1=NSN=C1NS(=O)(=O)C1=CC=C(N)C=C1
References
- General References
- BASG: Rokiprim (Sulfametrol, Trimethoprim) Intravenous Injection [Link]
- External Links
- ChemSpider
- 58466
- 37328
- ChEBI
- 88258
- ChEMBL
- CHEMBL2105398
- ZINC
- ZINC000000002099
- Wikipedia
- Sulfametrole
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Intravenous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.757 mg/mL ALOGPS logP 1.04 ALOGPS logP 1.05 Chemaxon logS -2.6 ALOGPS pKa (Strongest Acidic) 5.51 Chemaxon pKa (Strongest Basic) 1.9 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 107.2 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 69.46 m3·mol-1 Chemaxon Polarizability 26.36 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0090000000-03b5f50001452bcc32d6 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-000i-0390000000-b7480b8ed1038ab2db79 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4r-0930000000-fa6503d7af6b526ae2be Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0aba-0920000000-66a244859c45cc11eb3a Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-014i-9450000000-f7087b2dac4f8c83118d Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4m-3900000000-3e9fffc7c3db79862ab8 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 160.00148 predictedDeepCCS 1.0 (2019) [M+H]+ 162.35948 predictedDeepCCS 1.0 (2019) [M+Na]+ 168.45264 predictedDeepCCS 1.0 (2019)
Drug created at December 03, 2020 15:47 / Updated at May 07, 2021 21:09